0.300.00-1.42%
After-market 06:51:59 PM EDT 7/23/2024BTT
Plus500. 80% of retail CFD accounts lose money
0.30+0.02+8.14%
Official Close 03:59:59 PM EDT 7/23/2024BTT
| News | Analyst Data | Analyst Opinions | Insider Activity | Dividend Calendar |
New: Online Broker Comparison!Learn more about the best online brokers in our new comparison! Find out more!
On Monday 07/22/2024 the closing price of the Ginkgo Bioworks Holdings share was $0.30 on BTT.Compared to the opening price on Monday 07/22/2024 on BTT of $0.29, this is a gain of 4.36%.Ginkgo Bioworks Holdings's market capitalization is $604.31 M by 1.73 B shares outstanding.
Ginkgo Bioworks Stock Snapshot
0.30
Bid
300.00
Bid Size
0.31
Ask
1.00
Ask Size
7/23/2024
Date
6:51 PM
Time
0.00
Volume
0.30
Prev. Close
0.00
Open
604.43 M
Market Cap in USD
1.73 B
Number of Shares
0.26
52 Week Low
2.53
52 Week High
0.30
0.00
Dividend in USD
0.00
Dividend Yield
82.07
Free Float in %
-0.46
EPS in USD
0.58
Book Value per Share in USD
-0.15
Cash Flow per Share in USD
Ginkgo Bioworks Holdings NewsMore News
InvestorPlace
7 Meme Mania Stocks: Which Are FOMO and Which Are Free Money?
InvestorPlace
7 Sorry Biotech Stocks Set to Make Investors Sad
InvestorPlace
7 Sorry Biotech Stocks Set to Make Investors Sad
InvestorPlace
AI Demand and New Deals Make Ginkgo Bioworks Stock a Speculative Buy
InvestorPlace
DNA Stock: Ginkgo Bioworks Announces New Collaboration
Historical Prices for Ginkgo Bioworks Holdings
| Date | Open | Close | Daily High | Daily Low |
|---|
Price change over selected period:0%0
Ginkgo Bioworks Holdings Analyst Data
Total Analysts: 11
Buy Ratings: 3 Neutral Ratings: 3 Sell Ratings: 5
Analyst: {{ANALYST_DATA}}
Price-Target: {{PRICE_DATA}}
Rating: {{RATING_DATA}}
Price *Price Target
Lowest: 0.20 Median: 3.55 Highest: 14.50
*The average price target includes all analyst analysis, not just the most recent analysis presented in the chart.
Ginkgo Bioworks Holdings Analyst Opinions
- All
- Buy
- Hold
- Sell
| Date | Analyst | Rating | Price | |||
|---|---|---|---|---|---|---|
| 07/09/24 | Goldman Sachs | Maintained Sell | $0.300000011920929 | schlecht | ||
| 06/26/24 | BTIG Research | Maintained Sell | $0.200000002980232 | schlecht | ||
| 05/15/24 | BTIG Research | Downgraded to Sell | schlecht | |||
| 05/15/24 | Morgan Stanley | Maintained Hold | $1 | neutral | ||
| 05/10/24 | William Blair | Downgraded to Sell | schlecht | |||
| 01/22/24 | Goldman Sachs | Maintained Sell | $1.10000002384186 | schlecht | ||
| 11/14/23 | Raymond James Financial, Inc. | Downgraded to Hold | $2.5 | neutral | ||
| 11/09/23 | BTIG Research | Downgraded to Hold | neutral | |||
| 06/05/23 | Goldman Sachs | Maintained Sell | $1.25 | schlecht | ||
| 06/02/23 | Goldman Sachs | Downgraded to Sell | $1.25 | schlecht | ||
| 05/11/23 | William Blair | Downgraded to Hold | neutral | |||
| 11/29/22 | Berenberg | Maintained Buy | $6 | gut | ||
| 10/04/22 | Morgan Stanley | Maintained Hold | $5 | neutral | ||
| 08/16/22 | BTIG Research | Maintained Buy | $6 | gut | ||
| 08/16/22 | Raymond James Financial, Inc. | Maintained Buy | $14.5 | gut |
Ginkgo Bioworks Holdings Estimates* in USD
| 2024 | 2025 | 2026 | 2027 | |
|---|---|---|---|---|
| Revenue | 179 | 218 | 253 | - |
| Dividend | 0.00 | 0.00 | - | - |
| Dividend Yield (in %) | 0.00 % | 0.00 % | - | - |
| EPS | -0.29 | -0.18 | -0.08 | - |
| P/E Ratio | -0.97 | -1.56 | -3.73 | -1.49 |
| EBIT | -616 | -403 | -174 | - |
| EBITDA | -363 | -167 | -80 | - |
| Net Profit | -581 | -380 | -164 | - |
| Net Profit Adjusted | -566 | -431 | - | - |
| Pre-Tax Profit | -581 | -381 | -164 | - |
| Net Profit (Adjusted) | - | - | - | - |
| EPS (Non-GAAP) ex. SOE | - | - | - | - |
| EPS (GAAP) | -0.28 | -0.21 | - | - |
| Gross Income | 129 | 173 | - | - |
| Cash Flow from Investing | - | - | - | - |
| Cash Flow from Operations | - | - | - | - |
| Cash Flow from Financing | - | - | - | - |
| Cash Flow per Share | -0.18 | -0.10 | - | - |
| Free Cash Flow | - | - | - | - |
| Free Cash Flow per Share | - | - | - | - |
| Book Value per Share | 0.33 | 0.32 | 0.30 | - |
| Net Debt | -610 | -573 | -612 | - |
| Research & Development Exp. | 447 | 367 | - | - |
| Capital Expenditure | - | - | - | - |
| Selling, General & Admin. Exp. | 250 | 213 | - | - |
| Shareholder’s Equity | 717 | - | - | - |
| Total Assets | - | - | - | - |
| Previous Quarter ending 06/30/24 | Current Quarter ending 09/30/24 | Next Quarter ending 12/31/24 | Current Year ending 12/31/24 | Next Year ending 12/31/25 | |
|---|---|---|---|---|---|
| Earnings Estimates | |||||
| No. of Analysts | 5 | 5 | 5 | 5 | 5 |
| Average Estimate | -0.077 USD | -0.068 USD | -0.056 USD | -0.289 USD | -0.180 USD |
| Year Ago | -0.090 USD | -0.155 USD | -0.107 USD | -0.459 USD | - |
| Publish Date | 8/13/2024 | 11/11/2024 | 2/27/2025 | - | - |
| Revenue Estimates | |||||
| No. of Analysts | 5 | 5 | 5 | 6 | 6 |
| Average Estimate | 43 USD | 47 USD | 52 USD | 179 USD | 218 USD |
| Year Ago | 81 USD | 55 USD | 35 USD | 251 USD | - |
| Publish Date | 8/13/2024 | 11/11/2024 | 2/27/2025 | - | - |
* Average Estimates in Million (e.g. Revenue) or per share (e.g. Dividend). Source: FactSet
Income Statements in Mio. USD
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
| Sales | 251.46 | 477.71 | 313.84 | 0.00 |
| Change of sales in % | -47.36 | 52.21 | - | - |
| Gross profit on sales | 142.64 | 211.86 | 169.25 | 0.00 |
| Gross profit on sales change in % | -32.67 | 25.18 | - | - |
| Operating income | -672.23 | -2,161.92 | -1,827.87 | -0.01 |
| Operating income change in % | 68.91 | -18.28 | -36,557,240.00 | - |
| Income before tax | -892.94 | -2,121.40 | -1,838.12 | -0.01 |
| Income before tax change in % | 57.91 | -15.41 | -36,762,340.00 | - |
| Income after tax | -892.87 | -2,104.93 | -1,830.05 | -0.01 |
| Income after tax change in % | 57.58 | -15.02 | -36,600,840.00 | - |
Balance Sheet in Mio. USD
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
| Total liabilities | 568.19 | 803.04 | 503.61 | 1.23 |
| Long-term liabilities per share | 0.21 | 0.37 | 0.23 | 0.00 |
| Equity | 1,097.15 | 1,736.28 | 1,567.38 | 0.02 |
| Equity change in % | -36.81 | 15.34 | 7,526,725.00 | - |
| Balance sheet total | 1,665.34 | 2,539.32 | 2,070.99 | 1.25 |
| Balance sheet total change in % | -34.42 | 22.61 | 165,025.70 | - |
Key Data in USD
| 2023 | 2022 | 2021 | 2020 | |
|---|---|---|---|---|
| Sales per share | 0.13 | 0.28 | 0.19 | 0.00 |
| P/E ratio (year end quote, basic EPS) | - | - | - | - |
| P/E ratio (year end quote, diluted EPS) | - | - | - | - |
| P/E ratio (year end quote) | - | - | - | - |
| Dividend yield in % | 0.00 | 0.00 | 0.00 | - |
| Equity ratio in % | 65.88 | 68.38 | 72.69 | 1.59 |
| Debt ratio in % | 34.12 | 31.62 | 24.32 | 98.41 |
Ginkgo Bioworks Holdings Insider Activity
| Name | Date | shares traded | shares held | Price | type (sell/buy) | option |
|---|---|---|---|---|---|---|
| Dmytruk Mark E. | 07/01/2024 | 49,162.00 | 1,043,626.00 | 0.33 | Sell | No |
| Coen Steven P. | 07/01/2024 | 13,520.00 | 195,058.00 | 0.33 | Sell | No |
| Dmytruk Mark E. | 06/30/2024 | 22,916.00 | 1,091,153.00 | n/a | Buy | No |
| Dmytruk Mark E. | 06/30/2024 | 1,635.00 | 1,092,788.00 | n/a | Buy | No |
| Dmytruk Mark E. | 06/30/2024 | 65,450.00 | 1,050,112.00 | n/a | Buy | No |
| Dmytruk Mark E. | 06/30/2024 | 18,125.00 | 1,068,237.00 | n/a | Buy | No |
| Coen Steven P. | 06/30/2024 | 23,496.00 | 202,328.00 | n/a | Buy | No |
| Coen Steven P. | 06/30/2024 | 6,250.00 | 208,578.00 | n/a | Buy | No |
| Belldegrun Arie | 06/11/2024 | 105,263.00 | 194,925.00 | n/a | Buy | No |
| DEKKERS MARIJN E | 06/11/2024 | 105,263.00 | 386,480.00 | n/a | Buy | No |
| HENRY CHRISTIAN O | 06/11/2024 | 105,263.00 | 1,339,641.00 | n/a | Buy | No |
| Sankar Shyam | 06/11/2024 | 105,263.00 | 2,462,137.00 | n/a | Buy | No |
| Kewalramani Reshma | 06/11/2024 | 105,263.00 | 186,002.00 | n/a | Buy | No |
| SLOAN HARRY | 06/11/2024 | 105,263.00 | 823,803.00 | n/a | Buy | No |
| Dmytruk Mark E. | 06/02/2024 | 48,866.00 | 984,662.00 | 0.55 | Sell | No |
| Coen Steven P. | 06/02/2024 | 13,440.00 | 178,832.00 | 0.55 | Sell | No |
| Dmytruk Mark E. | 05/30/2024 | 22,917.00 | 1,031,890.00 | n/a | Buy | No |
| Dmytruk Mark E. | 05/30/2024 | 18,125.00 | 1,008,973.00 | n/a | Buy | No |
| Dmytruk Mark E. | 05/30/2024 | 1,638.00 | 1,033,528.00 | n/a | Buy | No |
| Dmytruk Mark E. | 05/30/2024 | 65,448.00 | 990,848.00 | n/a | Buy | No |
| Coen Steven P. | 05/30/2024 | 6,249.00 | 192,272.00 | n/a | Buy | No |
| Coen Steven P. | 05/30/2024 | 23,496.00 | 186,023.00 | n/a | Buy | No |
| DEKKERS MARIJN E | 05/15/2024 | 265,000.00 | 5,515,364.00 | 0.83 | Sell | No |
| DEKKERS MARIJN E | 05/13/2024 | 1,727,056.00 | 281,217.00 | 0.93 | Sell | No |
| SLOAN HARRY | 05/13/2024 | 297,619.00 | 718,540.00 | 0.91 | Buy | No |
Ginkgo Bioworks Dividend Calendar
| Date | Name | Dividend | *yield | Currency |
|---|---|---|---|---|
| 2023 | Ginkgo Bioworks Holdings | 0.00 | 0.00 | USD |
| 2022 | Ginkgo Bioworks Holdings | 0.00 | 0.00 | USD |
| 2021 | Ginkgo Bioworks Holdings | 0.00 | 0.00 | USD |
| 2020 | Ginkgo Bioworks Holdings | - | - | USD |
*Yield of the Respective Date
Ginkgo Bioworks Holdings Calendar
| Event | Estimate | Info | Date |
|---|---|---|---|
| Earnings Report | -0.077 USD | Q2 2024 Earnings Release | 08/13/2024 |
| Earnings Report | -0.068 USD | Q3 2024 Earnings Release | 11/11/2024 |
| Earnings Report | -0.056 USD | Q4 2024 Earnings Release | 02/27/2025 |
| Earnings Report | -0.057 USD | Q1 2025 Earnings Release | 05/08/2025 |
Ginkgo Bioworks Holdings Past Events
| Event | Actual EPS | Info | Date |
|---|---|---|---|
| Annual General Meeting | - | Annual General Meeting | 06/13/2024 |
Ginkgo Bioworks Holdings Profile
Ginkgo Bioworks Holdings, Inc. is a biotech company. Its platform is market agnostic and enables biotechnology applications across diverse markets, from food and agriculture to industrial chemicals to pharmaceuticals. It operates through the Cell Programming/Foundry, and Biosecurity segments. The company was founded by Jason Kelly, Reshma Shetty, Bartholomew Canton, Austin Che, and Thomas F. Knight, Jr. in 2008 and is headquartered in Boston, MA. .
Ginkgo Bioworks Holdings Shareholder
| Owner | in % |
|---|---|
| Freefloat | 82.07 |
| Baillie Gifford & Co. | 13.63 |
| ARK Investment Management LLC | 11.62 |
| ARK Investment Management LLC | 11.09 |
| Cascade Investment LLC | 8.89 |
| Viking Global Investors LP | 8.37 |
| Viking Global Investors LP | 8.37 |
| Baillie Gifford & Co. | 7.87 |
| The Vanguard Group, Inc. | 7.77 |
| Vanguard Group, Inc. (Subfiler) | 7.26 |
| Scottish Mortgage Investment Trust Plc | 5.60 |
| Anchorage Capital Group LLC | 4.09 |
| Thomas Knight | 4.00 |
| Nikko Asset Management Americas, Inc. | 3.27 |
| Vanguard Total Stock Market ETF | 2.62 |
Shareholder percentage totals can add to more than 100% because some holders are included in the free float.
